Associated Genetic Biomarkers
Cyclin A1 (CCNA1) is a gene that encodes a member of the cyclin family that functions as a regulator of cyclin-dependent kinases (CDKs). Cyclin A1 is expressed in the testis and brain and plays a role in the control of the germline meiotic cell cycle. Missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
CCNA1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CCNA1 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with CCNA1 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is CCNA1 Mutation .
Abemaciclib is the most frequent therapy in trials with CCNA1 as an inclusion criteria .
Significance of CCNA1 in Diseases
Malignant Solid Tumor +
CCNA1 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNA1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.